More on the News Industry Prospect In June 2024, Charles River announced a collaboration with MatTek Corporation to develop a New Approach Methodology inhalation toxicology test to reduce reliance on traditional animal research methods. The program will be funded through $1.3 million grant. Charles River currently carries a Zacks Rank #3 (Hold). The Inogen stock has surged 32.4% year to date. In the past 60 days, the bottom-line estimate for 2024 has narrowed from a loss of $2.56 per share to a loss of $2.4 ...

Outlook's 08/30/2023 CRL opened up a world of pain for its shareholders This is my second Outlook Therapeutics (NASDAQ:OTLK) article after 04/2023's "Outlook Therapeutics: August PDUFA For Wet AMD Blockbuster". In that article, I pegged Outlook as a high risk high reward bet on a successful PDUFA. I took the bullish bet, rating Outlook a Buy. In doing so, I noted: There is no wiggle room here. What happens if the FDA extends its PDUFA date by three months as quite common? What happens if the FDA issues a CR ...

The VCG collaboration is a project guided by Charles River's Alternative Methods Advancement Project ("AMAP"), an initiative focused on reducing the use of animals in research. The development is likely to boost the company's Discovery and Safety Assessment ("DSA") segment. As the company enters the next frontier of drug development, AMAP will facilitate strategic and purposeful investing to pave the path where more patients receive needed treatments and medicines safely, swiftly and successfully. Upholding ...

SAN DIEGO, June 06, 2024 (GLOBE NEWSWIRE) -- Johnson Fistel, LLP (www.johnsonfistel.com), a shareholder rights law firm, announces its continuing investigation of whether certain directors and officers of Charles River Laboratories International, Inc. (NYSE: CRL) breached their fiduciary duties to CRL and its shareholders. What can I do? If you are a current Charles River shareholder, you may have legal claims that may be brought on behalf of the company, against CRL's directors and officers. If you wish to ...

Charles River Laboratories International, Inc. (CRL) is well-poised for the coming quarters, on the back of its impressive strategic acquisitions. Stabilization of demand trends within the DSA (Discovery and Safety Assessment) arm is encouraging. The company's sound solvency also instils optimism. However, concerns remain over the adverse impacts of macroeconomic challenges as well as currency fluctuations. In the past year, this Zacks Rank #3 (Hold) company's shares have risen 9.4% compared with 6.1% growt ...

Charles River Laboratories' (CRL) Research Models and Services (RMS) arm continues to gain from the CRADL initiative. Yet, destocking efforts are denting growth in the Manufacturing Solutions business. The stock carries a Zacks Rank #3 (Hold) currently. Within Charles River's RMS segment, the company is witnessing strong growth in the insourcing solutions (IS) business led by the CRADL (Charles River Accelerator and Development Labs) initiative. These days, clients are increasingly adopting CRADL's flexible ...

Core Insights - Charles River Laboratories (CRL) reported total revenue of $1.01 billion for the quarter ending March 2024, reflecting a year-over-year decline of 1.7% [4] - The analysis of international revenue trends is crucial for understanding CRL's financial resilience and growth prospects [1][2] International Revenue Breakdown - Asia Pacific contributed $45.77 million, accounting for 4.5% of total revenue, which was a surprise decline of 17.66% compared to the expected $55.59 million [5] - Other International markets, including Brazil and Israel, generated $16.75 million, representing 1.7% of total revenue, with a significant surprise increase of 199.66% over the consensus estimate of $5.59 million [6] - Canada generated $110.4 million, making up 10.9% of total revenue, surpassing the expected $105.63 million by 4.52% [7] - Europe accounted for 27.3% of total revenue, translating to $276.32 million, exceeding expectations by 5.23% [8] Future Revenue Expectations - For the current fiscal quarter, total revenue is anticipated to be $1.04 billion, a decline of 1.9% year-over-year, with expected contributions from Asia Pacific (5.5%), Other International (0.2%), Canada (10.2%), and Europe (27.7%) [9] - For the full year, total revenue is projected at $4.22 billion, reflecting a 2.1% increase from the previous year, with specific contributions from various regions [10] Market Context - The interconnected global economy influences CRL's financial health and growth trajectory, highlighting the importance of international market penetration [2][3] - The company's reliance on international markets presents both opportunities and risks, making it essential to monitor international revenue trends for forecasting [11]

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.Zacks Premium includes access to the Zacks Style Scores as well.What are the Zacks Style Sc ...

Charles River Laboratories International, Inc. (CRL) reported first-quarter 2024 adjusted earnings per share (EPS) of $2.27, which reflected an 18.3% decrease year over year. However, the metric surpassed the Zacks Consensus Estimate by 10.7%.On a GAAP basis, earnings declined 35.3% year over year to $1.30 per share. The year-over-year decline in GAAP earnings was primarily due to lower revenues and gross and operating income.RevenuesRevenues in the first quarter totaled $1.01 billion, beating the Zacks Con ...

Company Participants Operator Todd Spencer During this call, we will primarily discuss non-GAAP financial measures, which we believe help investors gain a meaningful understanding of our core operating results and guidance. The non-GAAP financial measures are not meant to be considered superior to or a substitute for results from operations prepared in accordance with GAAP. In accordance with Regulation G, you can find the comparable GAAP measures and reconciliations on the Investor Relations section of our ...